United States - English - NLM (National Library of Medicine)

gland pharma limited - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel is indicated in combination with cisplatin. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (see clinical studies: breast carcinoma. ) paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless cl

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 30 mg in 5 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel is indicated in combination with cisplatin. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinica

United States - English - NLM (National Library of Medicine)

mylan institutional llc - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 30 mg in 5 ml - paclitaxel injection is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection is indicated in combination with cisplatin. paclitaxel injection is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unl

United States - English - NLM (National Library of Medicine)

hospira, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel is indicated in combination with cisplatin. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (see clinical studies: breast carcinoma .) paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. paclitaxel is indicated for the second-line treatment of aids-related kaposi’s sarcoma. paclitaxel injection, usp is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyl 35 castor oil, nf. paclitaxel injection, usp should not be used in patients with solid tumors who have baseline neutrophil counts of <1,500 cells/mm3 or in patients with aids-related kaposi’s sarcoma with baseline neutrophil counts of <1,000 cells/mm3 .

United States - English - NLM (National Library of Medicine)

alvogen inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 30 mg in 5 ml - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel is indicated in combination with cisplatin. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinica

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel -

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml - paclitaxel injection usp is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection usp is indicated in combination with cisplatin. paclitaxel injection usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors. (see clinical studies: breast carcinoma) paclitaxel injection usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have